Topiramate for Weight Loss:
Binge Eating, Carb Cravings & Qsymia®
Topiramate is an anticonvulsant prescribed off-label for weight loss, particularly effective for patients with binge eating patterns or carbohydrate cravings. Combined with phentermine it forms Qsymia®, an FDA-approved weight management medication.
How Topiramate Produces Weight Loss
Topiramate (brand name Topamax) is an anticonvulsant medication that produces clinically meaningful weight loss through multiple mechanisms: it reduces appetite through effects on GABA and glutamate receptors, decreases food reward signaling, and alters taste perception, making foods less appealing. Clinical trials show average weight loss of 5–9% of body weight with topiramate alone, and up to 10–11% when combined with phentermine as the FDA-approved combination Qsymia®.
Topiramate is particularly effective for patients who experience strong carbohydrate cravings, binge eating, Night Eating Syndrome, or food addiction patterns. The hedonic eating pathways it modulates are often the primary barrier for these patients. It is prescribed off-label for weight management and is also used alongside GLP-1 therapy for patients who need additional appetite suppression or who have specific eating pattern issues that GLP-1 alone does not fully address.
For patients who want the benefit of the FDA-approved Qsymia® combination but prefer flexibility in dosing or cost, the individual components (topiramate + phentermine) can be prescribed separately. Candidacy is evaluated based on your full health history, current medications, and cognitive tolerance. Because topiramate can affect word-finding and memory at higher doses, our team uses conservative dosing and monitors closely throughout your program. A full medication reconciliation is completed before prescribing.
| If you experience… | GLP-1 Likely Fits | Topiramate Likely Fits |
|---|---|---|
| Constant physical hunger between meals | ✓ | – |
| Eating when not physically hungry | – | ✓ |
| Specific craving for carbs or sweets | – | ✓ |
| Large appetite, difficulty feeling full | ✓ | – |
| Binge eating episodes or Night Eating Syndrome | – | ✓ |
| Type 2 diabetes or insulin resistance | ✓ | – |
Many patients have both patterns. Our medical team may combine GLP-1 therapy with topiramate for patients who need both metabolic and neurological support.
Topiramate is also FDA-approved for migraine prophylaxis. For patients who struggle with both weight and chronic migraines, our team can design a protocol that addresses both simultaneously, which means fewer total medications for the same therapeutic outcomes.
Topiramate directly modulates the reward pathways driving carbohydrate cravings and compulsive eating. For patients whose primary barrier is hedonic eating rather than metabolic hunger, it is often more targeted than a GLP-1 medication alone.
Many patients wonder whether off-label topiramate, the FDA-approved Qsymia® combination, or generic components separately is right for them. Our team walks you through the trade-offs based on your eating pattern, dosing needs, and cost considerations.
With expanding generic availability and the FDA-approved Qsymia® combination, topiramate-based weight management is more accessible than it once was. The right protocol still depends on your specific eating pattern, cognitive tolerance, and overall clinical picture.
Dr. Ashar N.
Dr. Ashar holds a Doctor of Nursing Practice and two national board certifications, one in family practice and one in psychiatric mental health.
She founded Tactus Health to close the gap she watched her own family fall through: symptoms that were real, labs that came back normal, and no one willing to connect the two.
She is responsible for the protocols our medical team follows, and for the training of the clinicians who deliver them. Holding both certifications is why those protocols treat hormones, mood, sleep and metabolism as one system rather than five separate appointments.
Topiramate FAQ
The most common include cognitive effects (word-finding difficulty, memory lapses, often called “Dopamax” by patients), tingling in the extremities (paresthesias), and increased kidney stone risk. These are dose-dependent and manageable with conservative dosing. Your provider monitors for these effects and adjusts dosing based on your tolerance throughout the program. Eye pressure changes (acute angle-closure glaucoma) are rare but require immediate attention if they occur.
Topiramate is sometimes used alongside GLP-1 therapy for patients who need additional appetite reduction or who have specific binge eating patterns that GLP-1 alone does not fully address. The two medications target different pathways: GLP-1 addresses metabolic hunger and gastric emptying, while topiramate targets reward-driven and craving-based eating. Combination safety is evaluated based on your full medication list and health history.
Yes. Night Eating Syndrome is characterized by consuming a large portion of daily calories after dinner or during night wakings, often driven by neurological reward and stress pathways rather than true hunger. Topiramate’s effects on GABA receptors and food reward signaling make it one of the most targeted medications for this pattern. Your provider will evaluate whether Night Eating Syndrome is a primary driver of your weight and whether topiramate or a combination protocol is the appropriate approach.
GLP-1 medications (semaglutide, tirzepatide) produce greater average weight loss and have a stronger evidence base. Topiramate is typically the right choice when GLP-1 is not appropriate, as an adjunct to GLP-1 for plateau patients, or when the patient’s specific eating pattern (carb cravings, binge eating, food addiction) is better targeted by topiramate’s mechanism. Your provider will recommend based on your clinical profile.
Topiramate is strictly contraindicated in pregnancy. It is a known teratogen carrying significant risk of oral cleft defects (cleft lip and palate) in the developing fetus. A negative pregnancy test and a confirmed plan for effective contraception are required for all female patients of childbearing age before prescribing topiramate. If you are planning pregnancy, discuss timing and a safe discontinuation plan with your provider before stopping contraception.
Topiramate is strictly contraindicated during pregnancy due to increased risk of oral cleft defects in the developing fetus. Negative pregnancy testing and effective contraception are required before initiating therapy. Common side effects include cognitive effects (word-finding difficulty, memory changes), tingling in extremities, kidney stones, and eye pressure changes. Seek immediate medical attention for sudden vision loss or eye pain (acute angle-closure glaucoma). Discontinue gradually under medical supervision to avoid seizure risk. Not recommended during breastfeeding. Individual results vary. Read full topiramate safety information →
Already on topiramate or considering Qsymia®? Our providers can review your dosing, monitor cognitive tolerance, and help refine your protocol for better long-term results.
Book Your Weight Loss Consultation
Free consultation with our licensed providers · No obligation
Book Free Consultation